Irina Ostrovnaya

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

48h-index10.8kcitations394works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bladder and Urothelial Cancer Treatments(159), Cancer Genomics and Diagnostics(93), Renal cell carcinoma treatment(88), Genetic factors in colorectal cancer(68), Urinary and Genital Oncology Studies(57)

Publications394 total

Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer
Clinical Cancer Research·2026
Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancer
Clinical Cancer Research·2026
Multiple myeloma risk linked to DNA damage response genes
Journal of Hematology & Oncology·2026Open Access
Multiple myeloma risk linked to DNA damage response genes
Figshare·2026Open Access
Multiple myeloma risk linked to DNA damage response genes
Figshare·2026Open Access
Additional file 2 of Multiple myeloma risk linked to DNA damage response genes
Figshare·2026Open Access
Additional file 2 of Multiple myeloma risk linked to DNA damage response genes
Figshare·2026Open Access
Additional file 1 of Multiple myeloma risk linked to DNA damage response genes
Figshare·2026Open Access
Additional file 1 of Multiple myeloma risk linked to DNA damage response genes
Figshare·2026Open Access
Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer
Nature Communications·2025Open Access
34Hypoxia and immune suppression shapes therapeutic outcomes and metastases in clear cell renal cell carcinoma
The Oncologist·2025Open Access
Long-term oncologic outcomes of metastatic clear-cell renal cell carcinoma after local therapy alone
Urologic Oncology Seminars and Original Investigations·2025Open Access
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer
Journal of Clinical Oncology·2025· 4 citedOpen Access
3102P Outcomes with enfortumab vedotin and pembrolizumab in metastatic urothelial carcinoma harboring FGFR3 or ERBB2 alterations
Annals of Oncology·2025
3089P Clinical outcomes with enfortumab vedotin and pembrolizumab in metastatic urothelial carcinoma and divergent differentiation or histologic subtypes
Annals of Oncology·2025
BET inhibitors reduce tumor growth in preclinical models of gastrointestinal gene signature–positive castration-resistant prostate cancer
Journal of Clinical Investigation·2025· 2 citedOpen Access
Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma
ESMO Open·2025· 1 citedOpen Access
A phase II study of lenvatinib plus pembrolizumab in patients with recurrent/metastatic salivary gland cancers.
Journal of Clinical Oncology·2025
Clinical validation of a multi-modal Ataraxis AI platform for recurrence prediction in early-stage breast cancer across multiple patient cohorts.
Journal of Clinical Oncology·2025· 1 cited
Cutaneous toxicity and clinical outcomes with enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma.
Journal of Clinical Oncology·2025
page 1 of 20Next →

Frequent Co-authors

Dean F. Bajorin(21), Gopa Iyer(20), Hikmat Al‐Ahmadie(19), David B. Solit(19), Bernard H. Bochner(16), Jonathan E. Rosenberg(16), Michael F. Berger(15), Victor E. Reuter(12), A. Ari Hakimi(12), K. Eugene(10), Emily C. Zabor(9), Jonathan Coleman(8), Paul Russo(8), Nikolaus Schultz(8), James J. Hsieh(7), Matthew I. Milowsky(7), Eugene J. Pietzak(7), Aditya Bagrodia(7), Guido Dalbagni(7), Maria E. Arcila(7)